Memantin Ratiopharm

Memantine Hydrochloride, the active ingredient in Memantin Ratiopharm, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients. It works by modulating glutamatergic neurotransmission, helping to reduce neuronal excitotoxicity associated with disease progression.

GNH USA supplies Memantin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Memantine Hydrochloride is used in the management of neurodegenerative disorders, particularly Alzheimer’s disease, by targeting glutamatergic excitotoxicity. - Alzheimer’s disease (moderate to severe): Improves cognition, functional abilities and behavioral symptoms in patients with moderate to severe disease. - Alzheimer’s disease (mild to moderate, adjunct therapy): May be added to cholinesterase inhibitors to enhance overall symptom control. - Behavioral symptoms in Alzheimer’s disease: Can help reduce agitation, aggression and other neuropsychiatric manifestations.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness, especially when standing quickly. - Headache: Mild to moderate intensity, often resolving without intervention. - Constipation: Decreased bowel movements that may improve with dietary fiber. - Fatigue: Generalized tiredness that can affect daily activities. - Confusion: Temporary disorientation, more frequent in the initial treatment period.

Serious or Rare Side Effects: - Seizures: New‑onset convulsive episodes requiring immediate medical attention. - Severe allergic reactions: Rash, swelling, or difficulty breathing indicating possible anaphylaxis. - Stevens‑Johnson syndrome: Rare skin blistering and mucosal involvement. - Hepatic dysfunction: Elevated liver enzymes or jaundice. - Suicidal thoughts: Emergence of depressive symptoms or suicidal ideation.

Memantine should be used with careful clinical monitoring. - Renal impairment: Adjust dose in patients with reduced kidney function. - Hepatic impairment: Monitor liver enzymes and consider dose modification. - History of seizures: Use cautiously and observe for increased seizure activity. - Concurrent NMDA antagonists: Avoid combining with other agents that block NMDA receptors. - Pregnancy and breastfeeding: Safety not established; weigh potential benefits against risks. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines. Major Interactions (Avoid): - Amantadine: Combined use can increase central nervous system adverse effects. - Other NMDA antagonists (e.g., ketamine): Additive neurotoxicity risk. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May lower memantine plasma concentrations. Moderate Interactions (Monitor Closely): - Anticholinergic agents: May diminish therapeutic benefit. - Diuretics: Potential for increased hypotension. - Antihypertensive drugs: Monitor blood pressure for additive lowering effect.